Zealand Pharma A/S

Business Description

Founded in Denmark in 1997, Zealand Pharma discovers and develops peptide-based treatments for gastrointestinal, metabolic, and other serious conditions with limited existing options. Its approved products include Zegalogue, used to treat severe low blood sugar, and a dasiglucagon-based system designed to work alongside insulin in artificial pancreas devices. The company is also advancing glepaglutide, a late-stage therapy for short bowel syndrome, and dasiglucagon as a potential treatment for a rare condition causing dangerously high insulin levels.